HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Rising incidence of thyroid cancer raises questions about treatment
-
- Allogeneic hematopoietic cell transplantation improved QOL-adjusted survival
- CCL3 levels independent prognostic marker in CLL
- FDA approves HPV vaccine for anal cancer
- Cancer care costs could increase by 66% in 2020
- Exploring treatment regimens for relapsed ALL William Wood, MD
- Cancer associated with increased risk for gastrointestinal infection
- Celecoxib chemoprevention may reduce nonmelanoma skin cancers
- Gastrointestinal stromal tumors may be linked to oxygen deficiency
-
- Problems common when viewing medical images from portable media
- Racial, ethnic disparities exist for early-stage HCC survival rates
- Tuberculosis linked to higher risk for lung cancer
- Anastrozole and exemestane yielded nearly identical clinical outcomes
- Aromatase inhibitors associated with increased CV risk in postmenopausal women
- Circulating tumor cells may have predictive, prognostic value
- DASISION: Dasatinib superior to imatinib in newly diagnosed CML
- Estrogen alone provides protective effect in breast cancer risk reduction
-
- Cabazitaxel: Just another taxane for prostate cancer? Laura Boehnke Michaud, PharmD; Adrienne H. Tam, PharmD, BCPS